LLT1 cell surface expression was significantly elevated in CD56+ NK cells of very high-risk (49.91% and 49.77%) and standard risk/low-risk (34.64% and 31.38%) ALL subjects at diagnosis (1BD) and after chemotherapy (2BD), respectively, as compared to healthy (12.64%) subjects (Figure 3E,F). This evidence concerns the gene NCAM1 and acute lymphoblastic leukemia.